# Affinivax

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/affinivax

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Website: www.affinivax.com
- Total disclosed funding: $346M
- Latest round: Series C (Jan 7, 2021)
- Investors on record: 14

## About

Affinivax, Inc. is a biotechnology company dedicated to the innovative development of next-generation vaccines, focusing on enhancing immunogenicity and serotype coverage for pneumococcal diseases.Founded in 2014 and headquartered in Cambridge, US, Affinivax, Inc. specializes in vaccine technologies, particularly the Multiple Antigen Presenting System (MAPS™). The company was acquired by GlaxoSmithKline Plc in May 2022 for USD 3.3 billion, which included an upfront payment of USD 2.1 billion, enabling further development of its vaccine portfolio.Affinivax, Inc. specializes in the development of innovative vaccine technologies, particularly targeting pneumococcal diseases. Its lead product, AFX3772, is a 24-valent pneumococcal vaccine candidate in phase II development, designed to enhance immune response and broad serotype coverage, particularly for adults over 50 and pediatric populations.Affinivax generates revenue through the advancement of its vaccine candidates, particularly AFX3772. The company’s structure includes strategic partnerships with healthcare providers and regulatory entities, expecting revenue from milestone payments linked to clinical trial successes. The acquisition by GlaxoSmithKline includes potential milestone payments totaling USD 0.6 billion based on pediatric clinical development achievements.Affinivax plans to leverage the recent acquisition by GlaxoSmithKline to enhance its MAPS platform, allowing for the continued development of a robust pipeline of innovative vaccines. With the substantial upfront payment of USD 2.1 billion, the company aims to expedite clinical trials and address significant public health challenges related to pneumococcal disease. Affinivax is focused on expanding its presence in the United States, where it has received Breakthrough Therapy designation for AFX3772, thereby enhancing its market potential.

## Funding rounds

- Series C, Jan 7, 2021, $226M — Bain Capital, T Rowe Price, Wellington Management, Viking Global Investors, Surveyor Capital, BlackRock, Foresite Capital, EcoR1 Capital, Rock Springs Capital, Cormorant Asset Management, Perceptive Advisors, Ziff Capital Partners, Logos Capital
- Series B, Apr 23, 2020, $120M — Viking Global Investors, Bain Capital Life Sciences, Ziff Capital Partners

## Investors

- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series B, Series C
- Bain Capital Life Sciences — Series B
- Ziff Capital Partners — Series B, Series C
- Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Series C
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series C
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series C
- Surveyor Capital — Series C
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series C
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series C
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series C
- Rock Springs Capital — Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series C
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series C
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series C